Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease.
BACKGROUND:Research from our laboratory, and that of other investigators, has demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of subjects with Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). We have extended these observations to investigate...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5841652?pdf=render |
id |
doaj-394aa43bdd2549e5a4f8d53f4c249dba |
---|---|
record_format |
Article |
spelling |
doaj-394aa43bdd2549e5a4f8d53f4c249dba2020-11-25T02:01:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019181510.1371/journal.pone.0191815Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease.Paul L WoodSoumya TippireddyJoshua FerianteRandall L WoltjerBACKGROUND:Research from our laboratory, and that of other investigators, has demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of subjects with Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). We have extended these observations to investigate the frontal cortex of subjects with Parkinson's disease (PD) and Lewy Body Disease (LBD), with and without coexisting pathologic features of AD. METHODS/PRINCIPAL FINDINGS:Utilizing a high-resolution mass spectrometry analytical platform, we clearly demonstrate that DAG levels are significantly increased in the frontal cortex of subjects with PD, LBD with intermediate neocortical AD neuropathology, and in LBD with established neocortical AD neuropathology. In the case of the PD cohort, increases in cortical DAG levels were detected in cases with no neocortical pathology but were greater in subjects with neocortical pathology. These data suggest that DAG changes occur early in the disease processes and are amplified as cortical dysfunction becomes more established. CONCLUSIONS:These findings suggest that altered DAG synthesis/metabolism is a common feature of neurodegenerative diseases, characterized by proteinopathy, that ultimately result in cognitive deficits. With regard to the mechanism responsible for these biochemical alterations, selective decrements in cortical levels of phosphatidylcholines in LBD and PD suggest that augmented degradation and/or decreased synthesis of these structural glycerophospholipids may contribute to increases in the pool size of free DAGs. The observed augmentation of DAG levels may be phospholipase-driven since neuroinflammation is a consistent feature of all disease cohorts. If this conclusion can be validated it would support utilizing DAG levels as a biomarker of the early disease process and the investigation of early intervention with anti-inflammatory agents.http://europepmc.org/articles/PMC5841652?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Paul L Wood Soumya Tippireddy Joshua Feriante Randall L Woltjer |
spellingShingle |
Paul L Wood Soumya Tippireddy Joshua Feriante Randall L Woltjer Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. PLoS ONE |
author_facet |
Paul L Wood Soumya Tippireddy Joshua Feriante Randall L Woltjer |
author_sort |
Paul L Wood |
title |
Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. |
title_short |
Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. |
title_full |
Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. |
title_fullStr |
Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. |
title_full_unstemmed |
Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. |
title_sort |
augmented frontal cortex diacylglycerol levels in parkinson's disease and lewy body disease. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
BACKGROUND:Research from our laboratory, and that of other investigators, has demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of subjects with Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). We have extended these observations to investigate the frontal cortex of subjects with Parkinson's disease (PD) and Lewy Body Disease (LBD), with and without coexisting pathologic features of AD. METHODS/PRINCIPAL FINDINGS:Utilizing a high-resolution mass spectrometry analytical platform, we clearly demonstrate that DAG levels are significantly increased in the frontal cortex of subjects with PD, LBD with intermediate neocortical AD neuropathology, and in LBD with established neocortical AD neuropathology. In the case of the PD cohort, increases in cortical DAG levels were detected in cases with no neocortical pathology but were greater in subjects with neocortical pathology. These data suggest that DAG changes occur early in the disease processes and are amplified as cortical dysfunction becomes more established. CONCLUSIONS:These findings suggest that altered DAG synthesis/metabolism is a common feature of neurodegenerative diseases, characterized by proteinopathy, that ultimately result in cognitive deficits. With regard to the mechanism responsible for these biochemical alterations, selective decrements in cortical levels of phosphatidylcholines in LBD and PD suggest that augmented degradation and/or decreased synthesis of these structural glycerophospholipids may contribute to increases in the pool size of free DAGs. The observed augmentation of DAG levels may be phospholipase-driven since neuroinflammation is a consistent feature of all disease cohorts. If this conclusion can be validated it would support utilizing DAG levels as a biomarker of the early disease process and the investigation of early intervention with anti-inflammatory agents. |
url |
http://europepmc.org/articles/PMC5841652?pdf=render |
work_keys_str_mv |
AT paullwood augmentedfrontalcortexdiacylglycerollevelsinparkinsonsdiseaseandlewybodydisease AT soumyatippireddy augmentedfrontalcortexdiacylglycerollevelsinparkinsonsdiseaseandlewybodydisease AT joshuaferiante augmentedfrontalcortexdiacylglycerollevelsinparkinsonsdiseaseandlewybodydisease AT randalllwoltjer augmentedfrontalcortexdiacylglycerollevelsinparkinsonsdiseaseandlewybodydisease |
_version_ |
1724958435234021376 |